Trial Profile
A PHASE 1 SINGLE-BLIND, SINGLE-SEQUENCE STUDY ASSESSING THE EFFECT OF TIVANTINIB ON THE QTC INTERVAL IN CANCER SUBJECTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2012 New trial record